Sareum Holdings PLC
(“Sareum” or the “Company”)
Sareum submits Clinical Trial Authorisation application to UK MHRA for development of TYK2/JAK1 inhibitor SDC-1801 and provides an Operational Update
Read more at globenewswire.comAll information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here
Sareum Holdings PLC
(“Sareum” or the “Company”)
Sareum submits Clinical Trial Authorisation application to UK MHRA for development of TYK2/JAK1 inhibitor SDC-1801 and provides an Operational Update
Read more at globenewswire.com| Symbol | Last | Chg | %Chg |
|---|---|---|---|
| SAR.LN | 22.721 | -0.279 | -1.21% |
| Sareum Holdings Plc | |||